Optimi Health (OPTI) AI Stock Analysis

• Market Cap: C$17.36M
• Dividend Yield: N/A
• Average Volume (3M): 17.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: 108.48%
• EPS Growth: -8.36%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 60
• Industry: Agricultural Farm Products
• EPS (TTM): -0.07
• Shares Outstanding: 96,438,170
• 10 Day Avg. Volume: 17,224
• 30 Day Avg. Volume: 17,239
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Optimi Health's financial performance is marked by revenue growth but hindered by persistent losses and cash flow challenges. Technical indicators show a neutral trend, and valuation metrics are unfavorable. However, recent corporate events, including FDA registration and global expansion, present potential growth opportunities, slightly offsetting the overall negative outlook.

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health (OPTI) is a health and wellness company focused on the production and distribution of natural and functional health products. Operating primarily in the nutraceutical and psychedelic sectors, Optimi Health aims to enhance physical and mental well-being through innovative formulations. The company's core products include functional mushrooms and psychedelic-based therapeutics, catering to a growing demand for alternative health solutions.

How the Company Makes Money

Optimi Health generates revenue through the sale of its health-focused products, primarily functional mushrooms and psychedelic-based treatments. The company capitalizes on the increasing consumer interest in natural and holistic health solutions by marketing its products directly to consumers, as well as through partnerships with health and wellness retailers. Additionally, Optimi Health leverages research and development collaborations to innovate and expand its product line, thus creating additional revenue streams. Key factors contributing to its earnings include its strategic partnerships, targeted marketing efforts, and its ability to adapt to regulatory changes in the burgeoning psychedelic health sector.

Optimi Health Financial Statement Overview

Summary

Optimi Health shows potential with revenue growth and strong equity levels. However, persistent losses, negative cash flows, and dependence on external financing pose significant financial challenges. Improving operational efficiency and cash management is vital for future success.

Income Statement

Optimi Health's revenue has shown growth from $0 in 2020 to $389,850 in 2024, indicating an upward trend. However, the company has consistently reported negative net income, with a significant net loss of $6,035,859 in 2024. The gross profit margin for 2024 is relatively healthy at 69.5%, but the absence of EBIT and negative EBITDA highlight challenges in operational efficiency.

Balance Sheet

The company maintains a high equity ratio, with stockholders’ equity consistently exceeding total liabilities, indicating financial stability. The debt-to-equity ratio is moderate at 0.29 in 2024, suggesting manageable leverage. However, the declining trend in total assets and stockholders' equity since 2021 should be monitored.

Cash Flow

Optimi Health's cash flow demonstrates a challenging picture with negative operating and free cash flows in all observed years, reflecting cash management issues. The operating cash flow to net income ratio is negative, underscoring cash flow inadequacy to cover net losses. Despite positive financing cash flows, reliance on external financing is evident.

Breakdown
Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
389.85K	181.09K	80.72K	0.00	0.00
	Gross Profit
270.91K	-157.04K	53.92K	-47.12K	-5.42K
	EBIT
0.00	-4.38M	-7.32M	-6.00M	-166.57K
	EBITDA
-4.74M	-4.42M	-7.03M	-5.95M	-161.14K
	Net Income Common Stockholders
-6.04M	-5.19M	-7.38M	-6.04M	-169.22K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
103.66K	1.34M	1.89M	12.43M	4.47M
	Total Assets
14.55M	16.49M	16.82M	23.46M	6.17M
	Total Debt
2.75M	1.71M	157.58K	250.84K	156.32K
	Net Debt
2.65M	362.46K	-1.73M	-8.18M	-4.31M
	Total Liabilities
4.98M	3.28M	797.66K	2.40M	882.66K
	Stockholders Equity
9.58M	13.21M	16.02M	21.07M	5.29M
Cash Flow		Free Cash Flow
-4.43M	-4.41M	-11.73M	-10.96M	-898.27K
	Operating Cash Flow
-4.28M	-3.60M	-4.58M	-6.02M	-143.45K
	Investing Cash Flow
-154.02K	-706.02K	-3.15M	-9.19M	-754.83K
	Financing Cash Flow
3.19M	3.76M	1.19M	19.18M	5.37M

Optimi Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Neutral. The current price of 0.2 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.19, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.40 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.24B	3.76	-41.88%	2.85%	17.01%	0.78%
TRIP	51 Neutral	C$14.03M	―	-30.44%	―	13.57%	-14.29%
OPTI	50 Neutral	C$17.36M	―	-58.39%	―	108.48%	-8.36%
RVV	46 Neutral	C$10.46M	―	-66.49%	―	―	-4.84%
CYBN	37 Underperform	$1.97M	―	-58.79%	―	―	51.37%
ENBI	36 Underperform	C$1.39M	―	-106.50%	―	-100.00%	11.63%

Optimi Health Corporate Events

Optimi Health Secures U.S. FDA Registration for Psychedelic Drug Supply

Optimi Health Corp. has obtained U.S. FDA Drug Establishment Registration, marking a significant regulatory milestone that allows the company to supply GMP-certified MDMA and psilocybin to authorized entities in the United States. This recognition positions Optimi to participate in the U.S. pharmaceutical supply chain, a crucial step as the U.S. market represents a significant opportunity for psychedelic-assisted therapies. The registration enables Optimi to engage in FDA filings, supply U.S. distributors, and file Abbreviated New Drug Applications (ANDAs) for generic formulations, enhancing its industry positioning and potential impact on stakeholders.

Spark’s Take on TSE:OPTI Stock

According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.

Optimi Health’s financial position reflects chronic losses and cash flow challenges, overshadowing its revenue growth. Technical indicators are weak, with the stock trading below key averages, reinforcing a bearish outlook. Valuation remains unattractive with a negative P/E. However, recent corporate advancements in psychedelic therapeutics present potential growth opportunities, slightly offsetting the overall negative outlook.

To see Spark’s full report on TSE:OPTI stock, click here.

Optimi Health Expands Psychedelic Therapeutics Globally

Optimi Health Corp. has announced significant advancements in its operations, including the expansion of MDMA exports to Australia and securing a BICON import permit for psilocybin, allowing its use for treatment-resistant depression. The company has also partnered with ATMA CENA Healthcare Solutions to supply psilocybin for clinical trials targeting major depressive disorder, marking progress towards broader regulatory approvals in Canada. Additionally, Optimi has completed a major harvest of Psilocybe cubensis, which will support upcoming clinical trials and international distribution.